Addex Therapeutics Plans Q1 2025 Results and Investor Call
Geneva, Switzerland - Addex Therapeutics (SIX/NASDAQ: ADXN), a biopharmaceutical company dedicated to developing innovative allosteric modulators targeting neurological disorders, is set to announce its Q1 2025 financial results on June 19, 2025. During this event, CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will update stakeholders on company developments and discuss their latest product pipeline.
Conference Call Overview
This will take place at 16:00 CEST, coinciding with various international times: 15:00 BST, 10:00 EDT, and 07:00 PDT. Participants are highly encouraged to register ahead of the conference to receive vital call details.
How to Join the Conference Call
To participate in the call, individuals must register using the link provided during the registration phase. Upon completing registration, they will receive unique Participant Dial-in numbers and a Personal PIN. Attendees should ensure they log in at least 10 minutes before the scheduled start, utilizing the access information sent by email during registration.
Webcast and Registration Information
Access the webcast by registering at one of the following links: Webcast Registration. For those wishing to attend the conference call, registration can be done through the following link: Conference Call Registration.
Company Insights
Addex Therapeutics plays a pivotal role in the biopharmaceutical industry, focusing on small molecule allosteric modulators for various neurological conditions. Their leading candidate, dipraglurant, is targeted at conditions relating to brain injury recovery, post-stroke recovery, and traumatic brain injury.
Strategic Advances
Working alongside Indivior, Addex is also developing a GABAB PAM drug candidate focusing on substance use disorders, which has completed IND enabling studies successfully. Furthermore, Addex is managing its independent GABAB PAM program aimed at chronic cough treatment.
Collaborations and Equity Stake
Addex holds a significant 20% equity stake in Neurosterix LLC, a private spin-out company creating allosteric modulators for schizophrenia and mood-related disorders. This collaboration emphasizes Addex's commitment to pioneering advancements in neurological research and treatment.
Contact Information
If you have any inquiries regarding this announcement or require further information, please reach out to:
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
+44 (0)7968 022075
msinclair@halsin.com
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call is meant to discuss Addex's Q1 2025 financial results and provide insights into the company's product pipeline.
How can I register for the conference call?
Participants can register in advance using the provided links to receive call-in details and a Personal PIN.
What key topics will be discussed during the call?
CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will cover financial results, company updates, and developments in their product offerings.
What are Addex's main projects?
Addex’s lead project includes dipraglurant, focusing on brain injury recovery, alongside other drug candidates aimed at neurological disorders.
How can I get more information about Addex Therapeutics?
Visit their official website at www.addextherapeutics.com for more details about their projects and updates.
